Serum endostatin levels are elevated in patients with soft tissue sarcoma

Area of Science:

• Oncology
• Biochemistry
• Molecular Biology

Background:

• Solid tumors rely on angiogenesis, with elevated proangiogenic cytokines observed across various histologies.
• Endostatin, an antiangiogenic fragment of collagen XVIII, may be generated by tumor proteases.
• This study investigated elevated circulating endostatin levels in patients with localized soft tissue sarcoma.

Purpose of the Study:

• To determine if circulating endostatin levels are elevated in patients with soft tissue sarcoma.
• To compare these levels with those of healthy controls.
• To explore the association between endostatin levels and tumor recurrence.

Main Methods:

• Preoperative serum samples from 25 soft tissue sarcoma patients were analyzed.
• Serum levels of endostatin, vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF) were measured using competitive enzyme immunoassays.
• Levels were compared to those of 34 age- and gender-matched healthy blood donors.

Main Results:

• Soft tissue sarcoma patients exhibited significantly higher serum endostatin levels compared to healthy controls (43.0 ng/mL vs. 25.8 ng/mL, P = 0.0002).
• Elevated levels of VEGF (P = 0.0002) and bFGF (P = 0.0001) were also observed in sarcoma patients.
• Endostatin levels exceeding 55 ng/mL were associated with an increased risk of tumor recurrence (P = 0.047).

Conclusions:

• Serum endostatin, VEGF, and bFGF levels are elevated in patients diagnosed with soft tissue sarcoma.
• Increased serum endostatin levels appear correlated with tumor aggressiveness.
• Further research is warranted to understand the role of these cytokines in sarcoma angiogenesis and their potential as therapeutic targets.